Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $79.1667.

Several analysts recently issued reports on the company. Guggenheim initiated coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research note on Wednesday, September 10th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Truist Financial initiated coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price target for the company. Finally, Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 price objective on the stock.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total value of $500,949.90. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at approximately $2,469,098.34. The trade was a 16.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of JANX. RA Capital Management L.P. boosted its stake in shares of Janux Therapeutics by 7.9% during the 1st quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company’s stock worth $302,122,000 after acquiring an additional 824,041 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Janux Therapeutics by 19.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company’s stock worth $98,673,000 after purchasing an additional 592,824 shares during the last quarter. Orbimed Advisors LLC boosted its position in Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock worth $43,163,000 after purchasing an additional 555,800 shares during the period. First Light Asset Management LLC grew its holdings in Janux Therapeutics by 110.0% during the first quarter. First Light Asset Management LLC now owns 658,824 shares of the company’s stock valued at $17,788,000 after purchasing an additional 345,042 shares during the last quarter. Finally, MPM Bioimpact LLC raised its position in shares of Janux Therapeutics by 146.6% in the first quarter. MPM Bioimpact LLC now owns 567,193 shares of the company’s stock valued at $15,314,000 after purchasing an additional 337,193 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

JANX stock opened at $28.72 on Tuesday. The stock has a market cap of $1.73 billion, a P/E ratio of -17.10 and a beta of 2.83. The firm has a 50 day simple moving average of $25.69 and a 200 day simple moving average of $25.03. Janux Therapeutics has a 52 week low of $21.73 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.